View printer-friendly version

Download PDF

Former DHHS Secretary, Dr. Louis W. Sullivan, Joins Board Of Directors Of Emergent BioSolutions

Extensive experience in Government, Medicine, and Industry Complements Emergent’s BioDefense and Commercial BioPharmaceutical Businesses

Gaithersburg, MD, June 21, 2006 – Emergent BioSolutions Inc., a privately-held biopharmaceutical company, announced today that Louis W. Sullivan, M.D. has been named to its Board of Directors. A physician, academician, and public servant, Dr. Sullivan served as Secretary of the U.S. Department of Health and Human Services from 1989 to 1993, pursuant to an appointment from then-President George H.W. Bush.

“We are extremely pleased to welcome Dr. Sullivan to Emergent’s Board of Directors,” said Fuad El-Hibri, Chairman and Chief Executive Officer of Emergent BioSolutions. “Dr. Sullivan is a renowned leader in matters of public health and safety both nationally and abroad. His academic and medical accomplishments and his distinguished public service have had a global impact on the advancement of healthcare and our Company is very fortunate to have access to his leadership and guidance.”

Dr. Sullivan currently serves as President Emeritus of Morehouse School of Medicine, where he previously served as President from 1981 to 1989 and again from 1993 to 2002. Dr. Sullivan is a Founder and Chairman of Medical Education for South African Blacks, Inc., is a former Trustee of Morehouse School of Medicine and Africare and is a director of the National Center for Addiction and Substance Abuse at Columbia University. Throughout his professional career, Dr. Sullivan has been awarded over 50 honorary degrees and has served as a Board member on numerous Fortune 500 companies and charitable organizations.

“I am pleased to join the Board of Emergent BioSolutions at a time in our history when biodefense and infectious diseases have become such important priorities,” said Dr. Sullivan. “Emergent has demonstrated an unwavering dedication to the protection of life through its longstanding commitment to the development and production of cutting-edge vaccines and other medical solutions.”

A native of Atlanta, Georgia, Dr. Sullivan graduated magna cum laude from Morehouse College in 1954 (with a B.S. in Biology), and earned his medical degree, cum laude, from Boston University School of Medicine in 1958. He is certified in internal medicine and hematology.

Dr. Sullivan has been actively involved in medical advancement for over 40 years, serving as an instructor of medicine at Harvard Medical School from 1963-64, an assistant professor of medicine at Seton Hall College of Medicine from 1964-66, and co-director of hematology at Boston University Medical Center in 1966. One year later, Dr. Sullivan founded the Boston University Hematology Service at Boston City Hospital. In addition, Dr. Sullivan held positions at the Boston University School of Medicine from 1966 through 1975, as assistant professor of medicine, associate professor of medicine, and professor of medicine.

Dr. Sullivan is a Director of United Therapeutics, BioSante Pharmaceuticals, Inhibitex, Inc., and Henry Schein, Inc. He recently retired from the Board of Directors of Bristol-Myers Squibb Company, 3M Corporation, Georgia Pacific Corporation, Cigna Corporation, and Equifax, Inc.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to protecting life through the development, manufacture, and commercialization of Immunobiotics™, which are novel products that direct the immune system to prevent and treat life-threatening diseases. These include products for prophylactic and therapeutic use against infectious diseases where there exists significant unmet or underserved medical needs and against biological agents which may potentially be used as weapons of bioterrorism. The company currently employs more than 450 people with sites in Maryland, Michigan, the United Kingdom, Germany, and the Republic of Singapore. More information about Emergent BioSolutions and its subsidiaries can be found at www.emergentbiosolutions.com.